← Leaderboards
Paul Michael Arnaboldi
New York Medical College
$5,503,528
Attributed
$8,807,743
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,807,743 · 10
By mechanism
R44$6,467,706 · 3
R43$1,527,682 · 4
R21$706,835 · 2
F32$105,520 · 1
Top collaborators
- Dino Di Carlo7 shared
- Alison Anne Mccormick3 shared
- Raymond James Dattwyler2 shared
Most similar at New York Medical College
Same institution · by research overlap
- Ira S. Schwartz$10,209,070
- Alison Anne McCormick$2,896,419
Others in their field
Top investigators on “Antigens”
- Barton F Haynes · Duke University$488,918,563
- Lawrence Corey · Fred Hutchinson Cancer Center$325,880,100
- Dennis R. Burton · Scripps Research Institute$291,395,948
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$245,204,950
- Jeffrey P Krischer · University Of South Florida$208,289,343
- Dan H. Barouch · Fred Hutchinson Cancer Center$124,506,327
Research focus
AntigensAntibodiesInfectionPreventPeptidesDetectionSpecificityProteinsPrototypeBaseSamplingEarly TreatmentEpitopesLyme DiseaseAntibioticsDiagnosisBorrelia BurgdorferiCellsCenters For Disease Control And Prevention (U.S.)DiagnosticImmunoglobulin GInnovationImmunoglobulin MLaboratories
Grant awards (20)
A point of care vertical flow assay for the direct detection of Babesia microti and the serodiagnosis of Lyme disease.$962,204
R44 · FY2025 · AI
Tobacco Mosaic Virus as a mucosal delivery platform for an intranasal vaccine against Pseudomonas aeruginosa$261,846
R21 · FY2025 · AI · contact PI
A point of care vertical flow assay for the direct detection of Babesia microti and the serodiagnosis of Lyme disease.$971,664
R44 · FY2024 · AI
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease$971,240
R44 · FY2023 · AI · contact PI
A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection$195,854
R21 · FY2023 · AI · contact PI
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease$986,480
R44 · FY2022 · AI · contact PI
A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection$249,135
R21 · FY2022 · AI · contact PI
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease$65,384
R44 · FY2022 · AI · contact PI
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease$1,000,000
R44 · FY2021 · AI · contact PI
A peptide-based point-of-care vertical flow assay for the rapid diagnosis of Lyme disease$300,000
R44 · FY2020 · AI · contact PI
An antigen-capture assay to screen donated blood for Babesia microti$299,812
R43 · FY2020 · AI · contact PI
An antigen-capture assay to screen donated blood for Babesia microti$299,812
R43 · FY2019 · AI · contact PI
Development of a cytokine release assay for the diagnosis of Lyme disease$605,367
R44 · FY2017 · AI · contact PI
Development of a cytokine release assay for the diagnosis of Lyme disease$605,367
R44 · FY2016 · AI · contact PI
Peptide-based Multiplex Assay for Lyme disease Serodiagnosis$176,282
R43 · FY2016 · AI · contact PI
A Rapid Point-of-Care Assay for the Diagnosis of Lyme Disease$151,776
R43 · FY2016 · AI · contact PI
Development of a Cytokine Release Assay as a Diagnostic Test for Lyme Disease$300,000
R43 · FY2013 · AI · contact PI
Development of a Cytokine Release Assay as a Diagnostic Test for Lyme Disease$300,000
R43 · FY2012 · AI · contact PI
The Role of CD8+ cells in the Development of Oral Tolerance$53,810
F32 · FY2010 · AI · contact PI
The Role of CD8+ cells in the Development of Oral Tolerance$51,710
F32 · FY2009 · AI · contact PI